Regeneron will report its Q3 earnings on October 30, marking the first quarter it fully books its share of Dupixent profits from Sanofi after repaying a $3.1 billion development balance. This change is expected to significantly boost collaboration revenue, which had been reduced by repayments in previous periods. Analysts anticipate strong year-over-year growth in earnings and revenue, partly reflecting this shift. Investors will also watch for updates on Eylea HD sales, margin improvements, and the upcoming FDA decision on cemdisiran, all of which could influence Regeneron's growth trajectory into 2027.
Regeneron Pharmaceuticals trades with a market cap of $82.88 billion and a dividend yield of 0.47% on Pluang as of Oct 26, 2026 20:51 WIB. The stock price is $811.77, up 0.84% in the last day, reflecting steady investor interest ahead of its Q3 earnings report on October 30. Sanofi, Regeneron's partner in Dupixent, has a market cap of $99.64 billion and a higher dividend yield of 5.82%, with its stock price at $41.75, up 0.36% on the same day. These figures highlight the significant scale and investor engagement in the companies involved in the Dupixent collaboration.
Regeneron Pharmaceuticals has extended its agreement with the U.S. government's BARDA to supply additional doses of Inmazeb, an FDA-approved antibody treatment for Ebola caused by Orthoebolavirus zairense. The expanded deal, valued at approximately $...
Regeneron's Libtayo (cemiplimab) demonstrates a growing overall survival benefit for high-risk cutaneous squamous cell carcinoma (CSCC) patients after nearly four years of follow-up in the Phase 3 C-POST trial. The data reveal a 37% reduction in deat...
